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Background: During most COPD exacerbations, patients continue to live in the community but there is little
information on changes in activity during exacerbations due to the difficulties of obtaining recent, prospective
baseline data.
Methods: Patients recorded on daily diary cards any worsening in respiratory symptoms, peak expiratory flow (PEF)
and the number of steps taken per day measured with a Yamax Digi-walker pedometer. Exacerbations were defined
by increased respiratory symptoms and the number of exacerbations experienced in the 12 months preceding the
recording of daily step count used to divide patients into frequent (> = 2/year) or infrequent exacerbators.
Results: The 73 COPD patients (88% male) had a mean (±SD) age 71(±8) years and FEV1 53(±16)% predicted. They
recorded pedometer data on a median 198 days (IQR 134–353). At exacerbation onset, symptom count rose by
1.9(±1.3) and PEF fell by 7(±13) l/min. Mean daily step count fell from 4154(±2586) steps/day during a preceding
baseline week to 3673(±2258) step/day during the initial 7 days of exacerbation (p = 0.045). Patients with larger falls
in activity at exacerbation took longer to recover to stable level (rho = −0.56; p < 0.001). Recovery in daily step
count was faster (median 3.5 days) than for exacerbation symptoms (median 11 days; p < 0.001). Recovery in step
count was also faster in untreated compared to treated exacerbation (p = 0.030).
Daily step count fell faster over time in the 40 frequent exacerbators, by 708 steps/year, compared to 338 steps/
year in 33 infrequent exacerbators (p = 0.002).
Conclusions: COPD exacerbations reduced physical activity and frequent exacerbations accelerate decline in
activity over time.
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Chronic obstructive pulmonary disease (COPD) is a glo-
bal cause of morbidity and mortality and an impairment
of health status [1]. Patients with COPD experience
episodes of acute worsening of respiratory symptoms
termed exacerbations, often triggered by infections [1].
Frequent exacerbations are a stable feature of the disease
[2] and have important impacts, such as, accelerating
decline in lung function, reducing quality of life and
impose higher health care utilization and costs [3-5].
Respiratory symptoms following an exacerbation can
take a number of weeks to return to baseline [6]. COPD* Correspondence: ayedh.ahmari.10@ucl.ac.uk
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unless otherwise stated.patients are less likely to go outside during an exacerba-
tion [7]. Also, patients with frequent exacerbations expe-
rience a significant faster decline in the amount of time
spent outdoors [7]. Depression is a significant comorbid
condition in COPD patients [8] and associated with in-
creased risk of exacerbation and hospitalisation [9].
COPD although primarily affecting the respiratory
system is known to have extra pulmonary effects such
reduced patient activity and skeletal muscle dysfunction.
Studies using accelerometers have shown that activity
declines at exacerbation especially in hospitalized pa-
tients in comparison to a month later [10,11] and over
time [12]. Low levels of physical activity assessed with a
multisensory arm-band (SenseWear) is strongly asso-
ciated with all-cause mortality in patients with COPDal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dently predicts exacerbation frequency [14].
Most clinical trials of early post-exacerbation pulmonary
rehabilitation (PR) trials have shown significant improve-
ment in exercise capacity, skeletal muscle strength, dys-
pnoea, quality of life and prevent de-conditioning [15-17].
Despite this evidence, patients treated in the community
for an exacerbation are not actively encouraged to main-
tain their physical activity during exacerbation recovery.
Possibly, information is lacking concerning the extent that
physical activity decreases during these non-hospitalized
events. These data would be needed for determining the
sample size required for a clinical trial of early PR in com-
munity treated exacerbations.
Prospective monitoring of physical activity is necessary
for quantifying the effects of exacerbation on activity as
baseline measurements falls over time and may vary with
season. Accelerometer-based monitoring devices are ex-
pensive and require regular clinic visits to download the
data and are therefore not ideal for the long-term use
required to prospectively capture relatively rare events
such as exacerbations. Accelerometers may slightly under-
estimate step count at the slow walking speeds expected
in COPD patients [18]. Pedometers are cheap and simple
to use, but there is little published data to support their
use in COPD patients. The aims of this study were to pro-
spectively evaluate daily step-count determined with a
simple pedometer, before and during the onset and re-
covery of an exacerbation. We have also evaluated the lon-
gitudinal trend of daily activity in patients with a history
of frequent and infrequent exacerbations.
Methods
Patient recruitment and characteristics
Seventy three patients were recruited from the London
COPD cohort. These patients recorded daily pedometry
data for a minimum of 35 days with the initial 7 days
considered as training and discarded for the purposes of
analysis. The study took place over 19 months between
April 2011 and November 2012.
All 199 patients in our rolling cohort were considered
for participation in this study. 24 patients were not eli-
gible as they used a walking support (cane or frame),
were confined to a wheel chair or used ambulatory
oxygen cylinders; 30 refused. We eventually provided pe-
dometers to 145 patients. Data was successfully acquired
from only 73 patients due to the following reasons a) 21
patients once issued refused to use the pedometer b) 19
patients lost their pedometers c) 23 patients recorded
less than 35 days of data whilst stable d) 9 pedometers
malfunctioned.
COPD was defined as a post-bronchodilator forced
expiratory volume in one second (FEV1) to forced vital
capacity (FVC) ratio below 0.70 and FEV1 expressed as apercentage of predicted FEV1 of less than 80%. Patients
were categorised as moderate, severe or very severe ac-
cording to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) classification [19]. Patients with a
history of another significant respiratory disease or con-
sidered unable to complete daily diary cards excluded
[4]. Patients were recruited when clinically stable, at
least six weeks after their last exacerbation.
At recruitment, age, gender, chronic respiratory symp-
toms and smoking history were noted, and height and
weight measured. FEV1 and FVC were measured with a
Vitalograph Gold Standard spirometer (Vitalograph Ltd,
Maids Moreton, UK).Daily monitoring
All patients were asked to complete a daily diary card on
which they recorded their morning post-medication peak
expiratory flow (PEF) measured with a mini-Wright peak-
flow meter (Clement-Clarke International Ltd, Harlow,
UK). They also recorded any worsening in their respira-
tory symptoms above normal and the number of hours
spent outside their home.
Patients were also instructed to wear a Yamax Digi-
walker SW-200 pedometer on the left side of their body
[20,21] all the time, except when sleeping or showering.
Pedometer placement was standardized by placing it on
the belt or waistband, in the midline of the thigh, con-
sistent with the manufacturer’s recommendation [22].
This pedometer has been shown to accurately measure
steps in free-living individuals [22] and in normal and
moderately obese patients and [23] detected differences
in physical activity of COPD patients recorded their
daily step count on the diary cards.Exacerbation definition
An exacerbation was defined as an increase for two con-
secutive days in respiratory symptoms, with at least one
major symptom (dyspnoea, sputum purulence or sputum
volume) plus either another major or a minor symptom
(wheeze, cold, sore throat, and cough) [6] .Five consecu-
tive symptom free days were required before identification
of the next exacerbation. Symptoms were disregarded in
identifying exacerbation onset if recorded continuously in
the preceding 5 days [24].A small proportion of exacer-
bations for which no diary-card symptoms had been re-
corded by questioning the patient at clinic visits about any
recent prescriptions [24] Symptom counts were obtained
by summating each increased respiratory symptom re-
corded on diary cards per day.
Patients were then divided into two groups, based on
the number of exacerbations in the 12 months preceding
the start of the study, those with 2 or more exacer-
bations per year were called frequent exacerbators and
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exacerbators [25].
Changes at exacerbations in daily step-count, symptoms
count, PEF and hours spent outdoors were assessed by
comparison of the average value over a 7 day baseline
period which started 2 weeks before onset with the aver-
age value over a 7 days exacerbation period starting on
the day of exacerbation onset. Recovery was determined
as the day after exacerbation onset when a 3 day moving
average of a parameter matched or exceeded its baseline
value. A moving average was used to avoid false early re-
coveries when step count or lung function improved for
just a single day, but then remained below baseline for a
few more days [6].
Ethics
The study was approved by the London-Hampstead re-
search ethics committee and all patients gave written in-
formed consent (REC 09/H0720/8). The current study is
entirely novel and has not been reported before except
in abstract form (European Respiratory Society Annual
Congress 2013, Barcelona, Spain 7–11 September).
Statistical analysis
Data were analyzed with STATA 8.2 (Stata Corporation,
College Station, TX) and PASW statistics V.21 (SPSS Inc.).
Normally distributed data are reported as a mean and
standard deviation (SD) or standard error of the mean
(SEM) and skewed data reported with a median and inter
quartile range (IQR). Comparisons were made by paired
Student t test or Wilcoxon signed-rank test as appropriate.
Stable mean daily step count and other patient characteris-
tics were related with a Pearson correlation or Spearman
rank correlation. Random effect linear regression modelsTable 1 Characteristics of the 73 COPD patients in the study
study
73 COPD patients Rem
Mean (±SD)
Age (years) 71.1 (±8.7)
FEV1 (l) 1.31 (±0.5)
FEV1 (% predicted) 52.9 (±16.5)
FVC (l) 2.79 (±0.9)
FEV1/FVC (%) 47.8 (±12.6)






Smoking at recruitment 35.6
SD=Standard Deviation, IQR=Inter-quartile range.were used to assess annual decline in daily stable step
count and whether the decline was faster in frequent than
infrequent exacerbators. A stable step count was defined
as outside a period starting 2 weeks before and ending
2 weeks after an exacerbation. Data from patients who ex-
perienced multiple exacerbations were averaged to avoid
bias through repeated measures. However, we analyzed
exacerbations as individual events when investigating
whether the characteristics of exacerbations (respiratory
symptoms, treatment, change in step count) was asso-
ciated with a fall in activity or recovery. Significant was
taken as p < 0.05.
Results
The 73 COPD patients (51 male, 22 female) studied had
moderate to very severe COPD (Table 1). Between 8th
April 2011 and 30th November 2012, daily step count
was recorded on 17,161 days with a median of 198 days
per a patient (IQR 134–353; range 29 to 540) days per
patient. There were no significant differences in the pa-
tient characteristics between the 73 patients involved in
this study and 126 patients excluded for reasons men-
tioned in the methods (Table 1).
Decline of daily step-count between patients with
frequent and infrequent exacerbations
Daily step-count was recorded in the stable state on
14,653 days (median 169 days per patient; IQR 113–285;
range 29–488) and for 2508 days with exacerbation
(median 21 days per patient; IQR 0–57; range 0–239).
Separately, daily step-count fell in the 33 infrequent
exacerbators by 338 steps/year [95% CI: −504 to −170]
compared to 708 steps/year [95% CI: −867 to −549] in the
40 frequent exacerbators (both p < 0.001). The annualand 126 COPD patients in the Cohort not recruited to the
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frequent exacerbators (p = 0.002; see Figure 1).
Time course of daily step-count at COPD exacerbation
Thirty seven patients experienced 79 exacerbations and
the characteristics of these patients are reported as
additional file table (see Additional file 1: Table S1). The
median time since the last exacerbation was 85.5 days
(IQR 42–193). The shortest interval was 15 days. There
was no record of a preceding exacerbation for 7 exacerba-
tions as these patients had been recently recruited. There
were no significant differences in patient characteristics
between these 37 patients and the 36 who did not expe-
rience an exacerbation except a higher FVC (L).
Table 2 shows that daily step-count, symptoms count
and PEF fell significantly at exacerbation but not hours
spent outdoors or whether the patient went out or not.
Daily step-count took a median 3.5 (IQR 1–8) days to re-
turn to baseline levels (see Figure 2A). Symptom count
rose and took 11 (IQR 8–17) days to resolve (Figure 2B)
and PEF (Figure 2C) took a median 4 (0–15) days to re-
turn to normal. Hours spent outdoors per day returned to
baseline levels within 1.4 (IQR 0.3-5.3) days (Figure 2D).
Recovery in step count was significantly earlier than symp-
toms (p < 0.001) but not PEF (p = 0.33) or hours spent
outdoors (p = 0.18).
The relationship between fall in daily steps–count and
respiratory symptoms and activity recovery
For the 79 exacerbations, those with the largest falls in daily
step count took longer to recover to baseline (rho = −0.56;
p < 0.001, Figure 3). During the 79 exacerbations, symp-
toms of dyspnoea were reported in 83.5%, sputumFigure 1 Daily step-count of 33 infrequent (number of days with data
exacerbators; predicted values obtained from the random effects, lin
corresponds to the start of the study.purulence in 43.0% and increase sputum volume in
67.1% as major symptoms. Minor symptoms of cold
were reported in 43.0%, wheezing in 49.4%, sore throat
in 21.5% and cough in 54.4%. No relationship was seen
between symptoms and fall in daily step count at ex-
acerbation or recovery in steps count with one excep-
tion the fall in step count and symptoms of a sore throat
(p = 0.037).
Activity and treatment
Fifty-seven exacerbations (11 antibiotics only; 7 oral cor-
ticosteroids only; 39 both antibiotics and oral steroids)
were treated in the COPD clinic and 22 were untreated.
Untreated exacerbations showed faster activity recovery
(median 0 days (IQR 0–3)) than treated exacerbations
(3 days (IQR 0 – 6)) (p = 0.030). Figure 4 shows that only
40.9% of untreated exacerbations were associated with a
fall in daily step count between baseline and exacerbation
compared to 68.4% for treated exacerbations (p = 0.025).
Discussion
This is the first and largest study to report fall and
recovery in daily walking activity using pedometry in
ambulatory COPD patients during non-hospitalized exac-
erbations. We found that daily step count fell by 480 steps
per day during exacerbation and recovery took a median
3.5 days. Over time, daily step count fell faster in patients
with frequent exacerbations. We also observed that exac-
erbations associated with a fall in daily step count were
more likely to be reported and received treatment.
Previous work on activity during exacerbation recovery
has been mainly based on the study of hospitalised
COPD patients. Pitta and colleagues saw improvements= 6878) and 40 frequent (number of days with data = 7775)
ear regression model (test of interaction, p = 0.002). Time 0
Table 2 Comparison between baseline and first 7 days of exacerbation (mean ± SD)
Stable Exacerbation Difference p-value
Daily step-counts (step/day) 4154 (±2586) 3673 (±2258) −480 (±1408) 0.045
Symptom count 0.4 (±0.7) 2.4 (±1.0) 1.9 (±1.3) <0.001
Peak Expiratory Flow (L/Min) 273 (±109) 266 (±108) −7 (±13) 0.005
Time outdoors (hours/day) 3.4 (±1.8) 3.2 (±1.8) −0.1 (±1.1) 0.51
Percentage of days on which patient went outdoors (%) 84.4 (24.2) 79.6 (26.1) −4.8 (±18) 0.13
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after discharge, but they observed no difference between
day 2 and day 7 [11]. Borges and colleagues have shown
that daily step count assessed with a tri-axial accelerom-
eter increased from 602 steps/day on the 2nd day of hospi-
talisation to 3,575 steps/day at one month post discharge
(p < 0.001) in 32 patients [10]. However, activity moni-
toring during exacerbations that required hospitalisations
may not reflect patient behaviour during exacerbations
taking place in the community as hospitalised patients are
likely to stay in bed for prolonged periods and not under-
take their usual activities. Furthermore, these hospital
based studies did not collect data prior to the onset of the
exacerbation. In a recently published small study, Ehsan
reported on activity levels in 17 patients who had just 27
symptom-define (EXACT) exacerbation in the community
[12] but daily data was lacking.
In this study we found that respiratory symptoms took
longer than daily step-count or time outdoors to return
to baseline values. The reasons for an earlier recovery inFigure 2 Time courses of daily step-count (A), symptoms (B), peak expiactivity are unclear, but may be due to the need to go
out of the home for social reasons or shopping, perhaps
to return to work or a desire to exercise after a period
of being housebound. It is also possible that the severity
of the respiratory symptoms during the later stages of
recovery is not sufficient to inhibit activity. In a previous
study, on 1465 exacerbations, we reported that patients
are significantly less likely to leave their home during an
exacerbation [7]. In this study, we observed a similar
trend, but it did not reach statistical significance due to
the smaller patient numbers studied. As daily step count
fell but hour’s outdoors was unchanged relative to the
baseline, it might be that patients with an exacerbation
used transport or walked more slowly when outside the
home. The actual intensity and nature of exercise under-
taken is a question that can only be addressed by more
sophisticated accelerometer devices.
The present study shows that the larger the fall in the
daily step count at exacerbation the longer it takes activity
to return to normal. This suggests that COPD patientsratory flow (C) and time spent outside (D) at COPD exacerbation.
Figure 3 Change in daily steps between baseline and exacerbation against time to recovery to baseline; 79 exacerbations (p < 0.001).
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stages of exacerbation since activity will return to normal
faster. Pulmonary rehabilitation programmes initiated
early post-exacerbation show a benefit compared to usual
care [15-17,26-28] possibly by avoiding muscle decondi-
tioning through inactivity during bed-rest [29]. However,
in the largest study to date, Eaton and colleagues found
no significant effect on acute health-care utilization, al-
though it was found to be safe and feasible [30].
Treated exacerbations were slower to recovery com-
pared to untreated exacerbations though our previous
work has suggested there is little difference in respiratory
symptoms between treated and untreated events [4]. TheFigure 4 The percentage of treated and untreated exacerbations that
exacerbation (average days 0 to 6).reasons why patients report some exacerbations to a
health care professional and not others have been unclear
and approximately 50% of exacerbations are unreported
[4,31]. Our findings suggest that impairment of daily acti-
vity may be a key factor in patients seeking additional
therapy for their exacerbation.
This study has shown for the first time that patients
who experienced frequent exacerbations have twice as
fast an annual decline in daily step-count than patients
with infrequent exacerbations. Frequent exacerbations
are known to accelerate both decline in FEV1 [25] and
rise in airway and systemic inflammation [3,32] with pa-
tients becoming housebound faster [7], and more likelydaily activity fell between baseline (average days −14 to −8) and
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cise mechanism of activity decline is unclear but it is
possible that prolonged recovery or non-recovery after an
exacerbation may contribute to this decline. In addition,
anxiety, depression and fatigue are associated with exa-
cerbations and any discourage patients from maintaining
activity. This may be particularly marked in more severe
patients with frequent exacerbations as they have sig-
nificantly more and longer hospital admissions, though
hospital admissions were not a subject for this study.
Cote and colleagues found a reduction in exercise capa-
city after an exacerbation, with a 72 m decline (20%) in
6MWD [35].
An important strength of the study was the prospective
daily monitoring of COPD patients to capture a baseline
activity level just before the exacerbation event started.
Baseline data collected away from the exacerbation may
not be valid as daily step count declines over time and
varies with seasonal changes [14]. Daily monitoring is also
essential when investigating exacerbation where symp-
toms recovery to normal in a few days. One limitation of
the study is that we did not include patients using ambula-
tory oxygen or walking supports or mild patients with
GOLD stage 1 COPD and our results should not be ex-
trapolated to these patient groups. However an important
feature of this study is that exacerbations treated in the
community were included and this makes the data ap-
plicable to the majority of exacerbations experienced by
COPD patients.Conclusions
Pedometer measurements can be used to track daily acti-
vity easily during COPD exacerbations that do not require
hospital admission. We have shown that exacerbations
reduce physical activity with patients recovering within a
3 to 4 day period. Frequent exacerbations also hasten a
decline in activity over time and potentially this patient
group would benefit from greater encouragement to con-
tinue exercising. Our results also show that daily activity
is a major drive for patients reporting exacerbation events
and seeking additional therapy. Thus, non-hospitalized
COPD exacerbations are key events that not only cause
symptomatic deterioration but also impair the patients’
activity.Additional file
Additional file 1: Characteristics of the 37 COPD patients in whom
pedometry data was recorded during at least one exacerbation.
Abbreviations
COPD: Chronic Obstructive Pulmonary Disease; PEF: Peak expiratory flow;
PR: Pulmonary rehabilitation; FEV1: Forced expiratory volume in one second;
FVC: Forced vital capacity; GOLD: Global initiative for chronic obstructivelung disease; SEM: Standard error of the mean; IQR: Inter quartile range;
SD: Standard deviation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
AA, JW, GD designed the study and analyzed the data; AA, AP, BK, AM, RS,
saw patients in clinic and collected data; AA, AP, BK, AM, RS, JW and GD
contributed to interpretation and drafting the manuscript for important
intellectual content. All authors read and approved the final manuscript.
Acknowledgments
The authors are grateful to all the patients in the London COPD cohort who
have contributed to the study, and willing give up their time to perform
assessment for this work.
Funding
The London COPD Cohort was funded by the Medical Research Council
(MRC), UK. Patient Cohort Grant G0800570/1. AA is funded by the Saudi
Ministry of Higher Education, the Kingdom of Saudi Arabia. The funding
body had no input into any aspect of this study.
Received: 4 February 2014 Accepted: 21 May 2014
Published: 2 June 2014
References
1. Wedzicha JA, Seemungal TA: COPD exacerbations: defining their cause
and prevention. Lancet 2007, 370:786–796.
2. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R,
Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF,
Wedzicha JA: Susceptibility to exacerbation in chronic obstructive
pulmonary disease. N Engl J Med 2010, 363:1128–1138.
3. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR,
Maccallum PK, Wedzicha JA: Airway and systemic inflammation and
decline in lung function in patients with COPD. Chest 2005,
128:1995–2004.
4. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA:
Effect of exacerbation on quality of life in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 1998,
157:1418–1422.
5. Simon-Tuval T, Scharf SM, Maimon N, Bernhard-Scharf BJ, Reuveni H,
Tarasiuk A: Determinants of elevated healthcare utilization in patients
with COPD. Respir Res 2011, 12:7.
6. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA: Time
course and recovery of exacerbations in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2000,
161:1608–1613.
7. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA:
Exacerbations and time spent outdoors in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2005, 171:446–452.
8. Norwood R: Prevalence and impact of depression in chronic obstructive
pulmonary disease patients. Curr Opin Pulm Med 2006, 12:113–117.
9. Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW, Wang C, Bourbeau J:
Independent effect of depression and anxiety on chronic obstructive
pulmonary disease exacerbations and hospitalizations. Am J Respir Crit
Care Med 2008, 178:913–920.
10. Borges RC, Carvalho CR: Physical activity in daily life in Brazilian COPD
patients during and after exacerbation. COPD 2012, 9:596–602.
11. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R: Physical
activity and hospitalization for exacerbation of COPD. Chest 2006,
129:536–544.
12. Ehsan M, Khan R, Wakefield D, Qureshi A, Murray L, Zuwallack R, Leidy NK:
A Longitudinal Study Evaluating the Effect of Exacerbations on Physical
Activity in Patients with Chronic Obstructive Pulmonary Disease. Ann Am
Thorac Soc 2013, 10:559–564.
13. Waschki B, Kirsten A, Holz O, MÃžller K-C, Meyer T, Watz H, Magnussen H:
Physical activity is the strongest predictor of all-cause mortality in
patients with COPDPhysical activity and all-cause mortality in COPDA
prospective Cohort Study. CHEST J 2011, 140:331–342.
Alahmari et al. BMC Pulmonary Medicine 2014, 14:98 Page 8 of 8
http://www.biomedcentral.com/1471-2466/14/9814. Moy ML, Danilack VA, Weston NA, Garshick E: Daily step counts in a US
cohort with COPD. Respir Med 2012, 106:962–969.
15. Man WD, Polkey MI, Donaldson N, Gray BJ, Moxham J: Community
pulmonary rehabilitation after hospitalisation for acute exacerbations of
chronic obstructive pulmonary disease: randomised controlled study.
BMJ 2004, 329:1209.
16. Murphy N, Bell C, Costello RW: Extending a home from hospital care
programme for COPD exacerbations to include pulmonary rehabilitation.
Respir Med 2005, 99:1297–1302.
17. Kirsten DK, Taube C, Lehnigk B, Jorres RA, Magnussen H: Exercise training
improves recovery in patients with COPD after an acute exacerbation.
Respir Med 1998, 92:1191–1198.
18. Furlanetto KC, Bisca GW, Oldemberg N, Sant’anna TJ, Morakami FK, Camillo
CA, Cavalheri V, Hernandes NA, Probst VS, Ramos EM, Brunetto AF, Pitta F:
Step counting and energy expenditure estimation in patients with
chronic obstructive pulmonary disease and healthy elderly: accuracy of
2 motion sensors. Arch Phys Med Rehabil 2010, 91:261–267.
19. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes
PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-
Roisin R: Global strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease: GOLD executive summary.
Am J Respir Crit Care Med 2013, 187:347–365.
20. Schneider PL, Crouter SE, Lukajic O, Bassett DR Jr: Accuracy and reliability
of 10 pedometers for measuring steps over a 400-m walk. Med Sci Sports
Exerc 2003, 35:1779–1784.
21. Crouter SE, Schneider PL, Karabulut M, Bassett DR Jr: Validity of 10
electronic pedometers for measuring steps, distance, and energy cost.
Med Sci Sports Exerc 2003, 35:1455–1460.
22. Schneider PL, Crouter S, Bassett DR: Pedometer measures of free-living
physical activity: comparison of 13 models. Med Sci Sports Exerc 2004,
36:331–335.
23. Swartz AM, Bassett DR Jr, Moore JB, Thompson DL, Strath SJ: Effects of
body mass index on the accuracy of an electronic pedometer.
Int J Sports Med 2003, 24:588–592.
24. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha
JA: Temporal clustering of exacerbations in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2009, 179:369–374.
25. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship
between exacerbation frequency and lung function decline in chronic
obstructive pulmonary disease. Thorax 2002, 57:847–852.
26. Troosters T, Gosselink R, Decramer M: Short- and long-term effects of
outpatient rehabilitation in patients with chronic obstructive pulmonary
disease: a randomized trial. Am J Med 2000, 109:207–212.
27. Nava S: Rehabilitation of patients admitted to a respiratory intensive care
unit. Arch Phys Med Rehabil 1998, 79:849–854.
28. Behnke M, Jorres RA, Kirsten D, Magnussen H: Clinical benefits of a
combined hospital and home-based exercise programme over
18 months in patients with severe COPD. Monaldi Arch Chest Dis 2003,
59:44–51.
29. Troosters T, Probst VS, Crul T, Pitta F, Gayan-Ramirez G, Decramer M,
Gosselink R: Resistance training prevents deterioration in quadriceps
muscle function during acute exacerbations of chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2010, 181:1072–1077.
30. Eaton T, Young P, Fergusson W, Moodie L, Zeng I, O’Kane F, Good N,
Rhodes L, Poole P, Kolbe J: Does early pulmonary rehabilitation reduce
acute health-care utilization in COPD patients admitted with an
exacerbation? A randomized controlled study. Respirology 2009,
14:230–238.
31. Langsetmo L, Platt RW, Ernst P, Bourbeau J: Underreporting exacerbation
of chronic obstructive pulmonary disease in a longitudinal cohort.
Am J Respir Crit Care Med 2008, 177:396–401.
32. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha
JA: Relationship between bacterial colonisation and the frequency,
character, and severity of COPD exacerbations. Thorax 2002, 57:759–764.33. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA: Relationship
between depression and exacerbations in COPD. Eur Respir J 2008,
32:53–60.
34. Baghai-Ravary R, Quint JK, Goldring JJ, Hurst JR, Donaldson GC, Wedzicha
JA: Determinants and impact of fatigue in patients with chronic
obstructive pulmonary disease. Respir Med 2009, 103:216–223.
35. Cote CG, Dordelly LJ, Celli BR: Impact of COPD exacerbations on
patient-centered outcomes. Chest 2007, 131:696–704.
doi:10.1186/1471-2466-14-98
Cite this article as: Alahmari et al.: Daily activity during stability and
exacerbation of chronic obstructive pulmonary disease. BMC Pulmonary
Medicine 2014 14:98.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
